following a full submission:
brolucizumab (Beovu®) is accepted for use within NHSScotland.
Indication under review: in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Non-inferiority of brolucizumab versus another anti-vascular endothelial growth factor medicine was demonstrated for mean change in best corrected visual acuity from baseline to week 48 in two phase III studies in patients with neovascular AMD.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- brolucizumab (Beovu)
- SMC ID:
- SMC2272
- Indication:
For the treatment of neovascular (wet) age-related macular degeneration (wAMD).
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 September 2020